Orthocell (ASX:OCC) said 10 surgeries have taken place in the US using its nerve repair product, Remplir, and it lodged 36 applications to hospital value assessment committees with three approvals already received, according to a Wednesday Australian bourse filing.
The hospitals targeted for value assessment committee approval have been sourced from the firm's network of US distributors.
The company hired two on-the-ground employees in the US, including a regional sales director, per the filing. It also shipped 4,000 Remplir units to its US logistics provider, Uniphar, for use in US surgical procedures.
Orthocell's shares rose nearly 2% in early trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.